Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.

[1]  N. Blacklock,et al.  The zonal anatomy of the prostate in man and in the Rhesus monkey (Macaca Mulatta) , 2004, Urological Research.

[2]  A. Weaver,et al.  Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. , 2001, The Journal of urology.

[3]  T. Stamey,et al.  Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. , 2001, The Journal of urology.

[4]  T. Stamey,et al.  Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. , 2000, The Journal of urology.

[5]  T. Stamey,et al.  Effect of Ageing on Morphologic and Clinical Predictors of Prostate Cancer Progression , 2000 .

[6]  T. Stamey,et al.  An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. , 2000, The Journal of urology.

[7]  P. Schellhammer,et al.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. , 2000, The Journal of urology.

[8]  T. Stamey,et al.  Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. , 2000, The Journal of urology.

[9]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[10]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[11]  P. Boyle,et al.  Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. , 1999, Urology.

[12]  A. Partin,et al.  Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. , 1999, Urology.

[13]  T. Stamey,et al.  Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. , 1998, The Journal of urology.

[14]  T. Stamey,et al.  Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. , 1998, The Journal of urology.

[15]  J. Hugosson,et al.  Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. , 1998, The Journal of urology.

[16]  D. Ransohoff,et al.  Early detection of prostate cancer. Serendipity strikes again. , 1997, JAMA.

[17]  F. Collins.  Preparing health professionals for the genetic revolution. , 1997, JAMA.

[18]  A. Rademaker,et al.  One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. , 1997, The Journal of urology.

[19]  C. Coley,et al.  Amiodarone and Thyroid Function , 1997, Annals of Internal Medicine.

[20]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[21]  D. Chan,et al.  Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. , 1997, JAMA.

[22]  B. Dalkin,et al.  Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less. , 1997, The Journal of urology.

[23]  T. Stamey,et al.  Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. , 1996, The Journal of urology.

[24]  T. Stamey,et al.  Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. , 1996, The Journal of urology.

[25]  P. Troncoso,et al.  Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. , 1995, The Journal of urology.

[26]  T. Stamey,et al.  Serum prostate-specific antigen and the biologic progression of prostate cancer. , 1995, Urology.

[27]  A S Whittemore,et al.  Prostate-specific antigen as predictor of prostate cancer in black men and white men. , 1995, Journal of the National Cancer Institute.

[28]  T. Wheeler,et al.  Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. , 1994, The Journal of urology.

[29]  R. Tibshirani,et al.  An Introduction to the Bootstrap , 1995 .

[30]  T. Stamey,et al.  Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.

[31]  R. Tibshirani,et al.  Confidence intervals based on bootstrap percentiles , 1993 .

[32]  M. Benson,et al.  The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. , 1992, The Journal of urology.

[33]  M. Riggs,et al.  Prostate‐specific antigen levels from completely sectioned, clinically benign, whole prostates , 1991, Cancer.

[34]  T. Hastie,et al.  Statistical Models in S , 1991 .

[35]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[36]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[37]  T. Stamey,et al.  Capsular Penetration in Prostate Cancer. Significance for Natural History and Treatment , 1990, The American journal of surgical pathology.

[38]  J. Oesterling,et al.  Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. , 1988, The Journal of urology.

[39]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[40]  T. Grogan,et al.  Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes. , 1985, American journal of clinical pathology.

[41]  A. Ng,et al.  Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. , 1984, American journal of clinical pathology.

[42]  D. M. Ellis,et al.  Applied Regression Analysis , 1968 .